Expanded investigational programmes are assessing outcomes across larger cohorts. Retatrutide remains investigational and is not approved for human use in most jurisdictions.
This summary describes publicly reported investigational research on retatrutide (LY3437943). Full study design, endpoints and outcome data can be added here through the classic editor.
Published trial data provides context for laboratory reference material and helps researchers relate in-vitro findings to the wider investigational programme. See our References page for the underlying literature.
Educational summary only — not a therapeutic claim and not medical advice.
Educational summary of publicly reported research. Not a therapeutic claim and not medical advice. Retatrutide is investigational and not approved for human use in most jurisdictions.
Mid-stage investigational trials explored a range of retatrutide doses and metabolic endpoints in adults with obesity, with results…
Initial investigational studies characterised the pharmacokinetics and tolerability of retatrutide (LY3437943), establishing the groundwork for later dose-ranging research.